- Home
- SNT vs TIL Comparison
SNT vs TIL Comparison
Compare SNT & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | TIL |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 74.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNT | TIL |
|---|---|---|
| Price | $3.38 | $8.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 37.7K | ★ 61.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.57 | $5.67 |
| 52 Week High | $5.34 | $42.75 |
Technical Indicators
Market Signals| Indicator | SNT | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 56.40 |
| Support Level | $3.25 | $6.85 |
| Resistance Level | $3.60 | $9.81 |
| Average True Range (ATR) | 0.27 | 0.58 |
| MACD | -0.05 | 0.16 |
| Stochastic Oscillator | 23.31 | 60.26 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.